CSIMarket
 
Recursion Pharmaceuticals Inc   (RXRX)
Other Ticker:  
 
 
Price: $12.8100 $-0.65 -4.829%
Day's High: $13.63 Week Perf: -13.21 %
Day's Low: $ 12.65 30 Day Perf: 36.13 %
Volume (M): 9,171 52 Wk High: $ 16.75
Volume (M$): $ 117,481 52 Wk Avg: $8.51
Open: $13.44 52 Wk Low: $4.54



 Market Capitalization (Millions $) 2,660
 Shares Outstanding (Millions) 208
 Employees -
 Revenues (TTM) (Millions $) 45
 Net Income (TTM) (Millions $) -328
 Cash Flow (TTM) (Millions $) -158
 Capital Exp. (TTM) (Millions $) 13

Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals Inc. is a biotechnology company that uses advanced artificial intelligence (AI), automation, and drug discovery platforms to develop new treatments for various diseases. The company focuses on identifying and targeting rare genetic diseases, as well as finding potential therapeutics for other complex diseases.

Recursion Pharmaceuticals utilizes high-throughput robotic imaging and combines it with deep learning algorithms to rapidly screen thousands of disease models in order to identify novel drug candidates. Their unique approach enables them to generate vast amounts of biological data that can be analyzed to uncover new insights and potential treatments.

The company has a diverse pipeline of drug candidates at various stages of development, covering a range of diseases like neurodegenerative disorders, cancer, and genetic diseases. They collaborate with pharmaceutical companies, academic institutions, and biotech partners to accelerate the discovery and development of new therapeutic options.

Recursion Pharmaceuticals aims to revolutionize drug discovery by integrating modern technology with biology to unlock new breakthroughs in treating diseases that were previously considered challenging. Their innovative approach holds the potential to provide hope for patients suffering from complex diseases and improve the overall efficiency of drug development.


   Company Address: 41 S Rio Grande Street Salt Lake City, 84101 UT
   Company Phone Number: 269 - 0203   Stock Exchange / Ticker: NASDAQ RXRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc Struggles with Financial Losses in Fourth Quarter of 2023: A Closer Look at the TechBio Company's Fiscal Performance

Recursion Pharmaceuticals Inc, a leading clinical stage TechBio company focused on decoding biology for drug discovery, has reported its financial results for the fourth quarter and fiscal year ending December 31, 2023. The company's weak business performance led to a rise in losses for the most recent fiscal period. It experienced a shortfall per share of $-0.35, compared to $-0.30 in the previous year, while its revenue declined by 20.364% to $10.89 million from $13.68 million.
However, the third quarter showed some positive signs for Recursion Pharmaceuticals Inc, with revenue growth of 3.399% from $10.53 million and an improvement in earnings per share from $-0.43 per share. But for the most recent fiscal period, the company incurred a net loss of $-92.996 million, which was larger than the $-57.492 million loss recorded in the previous year.

Product Service News

Recursion Unveils LOWE: A Leap Forward in Drug Discovery

Published Mon, Jan 8 2024 3:59 PM UTC

Recursion Unveils Groundbreaking Drug Discovery Software at J.P. Morgan Healthcare ConferenceAt the highly anticipated J.P. Morgan Healthcare Conference, Recursion made waves by introducing its innovative LOWE software. The company, renowned for its cutting-edge approach to drug discovery, showcased live demonstrations of LOWE and raised eyebrows with its impressive capabili...

Partnership

Entering the Era of Recursion: Unveiling a Cutting-Edge Fibrosis Breakthrough and Pioneering Partnership

Published Thu, Jan 4 2024 12:59 PM UTC

In an exciting revelation, Recursion Pharmaceuticals has introduced a groundbreaking chemical entity for combating fibrotic diseases in its late-stage discovery pipeline. Alongside this significant milestone, the company has acquired a potential first-in-class novel molecule through a collaborative partnership with Bayer. This dual achievement is poised to revolutionize the ...

Partnership

Revolutionizing Drug Discovery: Recursion and Enamine Unite to Transform Compound Library Screening

Published Wed, Dec 20 2023 12:59 PM UTC

Recursion and Enamine Collaborate to Drive Drug Discovery with Enriched Compound Libraries
In a significant development for the global drug discovery industry, Recursion Pharmaceuticals Inc has joined forces with Enamine, a leading chemistry-driven drug discovery and preclinical development company. This collaboration aims to leverage Recursion's innovative MatchMaker to...

Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc. Faces Significant Decline in Revenue Throughout Q3 Earnings Season

Investors have been eagerly awaiting the financial results of Recursion Pharmaceuticals Inc for the third quarter of 2023. Although the numbers may not seem entirely promising at first glance, there are several positive trends to consider.
One of the key highlights of the financial report is the company's increased deficit per share, which rose to $-0.43 compared to $-0.35 from the previous year. While this may initially raise eyebrows, it is important to note that the deficit from the previous financial reporting period was $-0.38 per share. This shows a slight improvement in the company's financial situation and reflects their efforts to optimize their operations.






 

Recursion Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com